Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
